If you have been reading about triple agonist and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
Characterising a peptide of this size relies on a combination of chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the intact molecule from related impurities, while electrospray mass spectrometry confirms molecular mass and detects truncation or oxidation products. Peptide mapping after enzymatic digestion verifies the amino acid sequence and locates modified residues. Because the molecule carries a lipid chain, assays must also distinguish the correctly conjugated product from incompletely acylated species.
Peptides in this class degrade mainly through hydrolysis, oxidation, and aggregation. The lipid modification improves plasma residence time but can also promote self-association in aqueous solution at higher concentrations. Oxidation of methionine and deamidation of asparagine residues are common chemical liabilities that accumulate during storage. Stability studies therefore track purity loss, aggregate formation, and changes in receptor-binding potency over time under defined temperature and humidity conditions.
Solid peptide is generally held as a lyophilised powder at low temperature to slow degradation, with desiccant to limit moisture uptake. Reconstituted solutions are less stable and are usually kept refrigerated and protected from light for short periods. Repeated freeze-thaw cycles are avoided because they encourage aggregation. Laboratory handling includes work in a fume hood or laminar flow cabinet to limit inhalation and contamination. Weighing and transfer steps are performed with antistatic tools to reduce static-driven loss of fine powder.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Not a small molecule |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist activity |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Soluble in water | Also in aqueous buffers |
| Storage | −20 °C or below | Protect from light and moisture |
Retatrutide is an investigational synthetic peptide engineered to activate three distinct hormone receptors within a single molecule. It targets the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor simultaneously. This triagonist design distinguishes it from earlier incretin-based compounds that act on one or two of these pathways. Structural modifications relative to native gut hormones extend its residence time in circulation. The molecule remains under clinical evaluation and is not approved for any indication.
Receptor activation produces downstream effects that differ by tissue. GLP-1 receptor signaling influences appetite regulation and insulin secretion in a glucose-dependent manner. GIP receptor activity contributes to metabolic handling of nutrients and may modulate adipose tissue. Glucagon receptor engagement raises energy expenditure and promotes hepatic lipid turnover, though the balance among these actions in humans is still being characterized. Preclinical models showed reductions in body weight and improved glycemic markers.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
=== Flower === The flowers are usually found on thick stems rising several centimetres above the leaves. They are showy and grow up to 35 cm (14 in) in diameter. Some cultivated varieties have extraordinary numbers of petals. For example, the Chinese variety qian ban lian ("thousand petals lotus") can have between 3,000 and 4,000 petals in a single blossom and the Japanese variety ohmi myoren ("strange lotus") can have between 2,000 and 5,000 petals, the greatest number recorded for any species of plant. Lotus flowers regulate their temperature to within a narrow range, maintaining temperatures of 30–35 °C (86–95 °F), even with air temperatures as low as 10 °C (50 °F). Researchers think that this may be to attract cold-blooded insect pollinators to the flowers. Nelumbo nucifera is not closely related to other plants known to be thermogenic.
== Sierra Leone == Amadu Wurie - Educationist and politician, First Minister of Education and later Minister of Interior of Sierra Leone Sir Banja Tejan-Sie - Politician and lawyer. former vice president under SLPP (1953–1956), former chief justice and Governor-General of Sierra Leone Mohamed Juldeh Jalloh – Current vice president, Republic of Sierra Leone Abass Bundu – Current Speaker of Parliament Sierra Leone, former minister of foreign affairs, former Executive Secretary of the Economic Community of West African States Ibrahim Bundu - former majority leader of the Sierra Leone Parliament, Sierra Leone Abdulai Hamid Charm - former chief justice, Sierra Leone Umu Hawa Tejan-Jalloh – former chief justice, Diplomat, Sierra Leone Miatta Maria Samba - Sierra Leonian jurist and current judge at the International Criminal Court (ICC). Sulaiman Tejan-Jalloh – politician and Diplomat, former Minister of Transport and Communications and former ambassador to US, Sierra Leone Neneh Cherry (birth name Neneh Mariann Karlsson) – Singer-songwriter, rapper, occasional DJ and broadcaster, Sweden Titiyo (birth name Titiyo Yambalu Felicia Jah) – singer and songwriter, Sweden Alpha Timbo – Politician, educationist, lecturer and trade unionist. Minister of Primary and Secondary Education, former Minister of Labor and Industrialization, Sierra Leone Chernor Bah - Minister of Information and Civic Education Chernor Maju Bah – lawyer and politician.
=== Poisoning of Emilian Gebrev === In the aftermath of the Skripal poisoning, investigative journalists were able to track some of the people involved also in Bulgaria. This is how another suspected poisoning case dating back to April 2015 during their stay in the country was linked to the Novichok nerve agent. The victim was the Bulgarian arms dealer Emilian Gebrev, who shared two hypotheses why he might have been attacked: The first one links to the fact that his arms manufacturing company Dunarit exports defense equipment to Ukraine. The other one relates to an attempt by an offshore company to take over Dunarit. The takeover attempt was ultimately linked to the influential Bulgarian politician and oligarch Delyan Peevski who has historically been funded by Russia's state-owned VTB Bank. In November 2023 Bulgaria sought the extradition of three Russian GRU officers, Sergey Fedotov, Georgi Gorshkov and Sergey Pavlov, suspected of the poisoning incident. Sergei Fedotov was also the alias used by one of the assassins in the Salisbury poisonings.
Sources: en.wikipedia.org
power reactors are intended to produce heat for nuclear power, either as part of a generating station or a local power system such as a nuclear submarine. research reactors are intended to produce neutrons and/or activate radioactive sources for scientific, medical, engineering, or other research purposes. breeder reactors are intended to produce nuclear fuels in bulk from more abundant isotopes. The better known fast breeder reactor makes 239Pu (a nuclear fuel) from the naturally very abundant 238U (not a nuclear fuel). Thermal breeder reactors previously tested using 232Th to breed the fissile isotope 233U (thorium fuel cycle) continue to be studied and developed. While, in principle, all fission reactors can act in all three capacities, in practice the tasks lead to conflicting engineering goals and most reactors have been built with only one of the above tasks in mind. (There are several early counter-examples, such as the Hanford N reactor, now decommissioned). As of 2019, the 448 nuclear power plants worldwide provided a capacity of 398 GWE, with about 85% being light-water cooled reactors such as pressurized water reactors or boiling water reactors. Energy from fission is transmitted through conduction or convection to the nuclear reactor coolant, then to a heat exchanger, and the resultant generated steam is used to drive a turbine or generator.
== Epidemiology == The allergic diseases—hay fever and asthma—have increased in the Western world over the past 2–3 decades. Increases in allergic asthma and other atopic disorders in industrialized nations, it is estimated, began in the 1960s and 1970s, with further increases occurring during the 1980s and 1990s, although some suggest that a steady rise in sensitization has been occurring since the 1920s. The number of new cases per year of atopy in developing countries has, in general, remained much lower.
4-Aminobenzoic acid (also known as para-aminobenzoic acid or PABA because the two functional groups are attached to the benzene ring across from one another in the para position) is an organic compound with the formula H2NC6H4CO2H. PABA is a white crystalline solid, although commercial samples can appear gray. It is slightly soluble in water. It consists of a benzene ring substituted with amino and carboxyl groups. The compound occurs extensively in the natural world. In industry, PABA is prepared mainly by two routes: Reduction of 4-nitrobenzoic acid Hoffman degradation of the monoamide derived from terephthalic acid. Food sources of PABA include liver, brewer's yeast (and unfiltered beer), kidney, molasses, mushrooms, and whole grains. Other food sources of PABA include spinach and oat seeds.
Sources: en.wikipedia.org
The values do not agree with those now known for 255No, although they do agree with those now known for 257No, and while this isotope probably played a part in this experiment, its discovery was inconclusive. Work on element 102 also continued in Dubna, and in 1964, experiments were carried out there to detect alpha-decay daughters of element 102 isotopes by synthesizing element 102 from the reaction of a 238U target with neon ions. The products were carried along a silver catcher foil and purified chemically, and the isotopes 250Fm and 252Fm were detected. The yield of 252Fm was interpreted as evidence that its parent 256No was also synthesized: as it was noted that 252Fm could also be produced directly in this reaction by the simultaneous emission of an alpha particle with the excess neutrons, steps were taken to ensure that 252Fm could not go directly to the catcher foil. The half-life detected for 256No was 8 s, which is much higher than the more modern 1967 value of (3.2 ± 0.2) s. Further experiments were conducted in 1966 for 254No, using the reactions 243Am(15N,4n)254No and 238U(22Ne,6n)254No, finding a half-life of (50 ± 10) s: at that time the discrepancy between this value and the earlier Berkeley value was not understood, although later work proved that the formation of the isomer 250mFm was less likely in the Dubna experiments than at the Berkeley ones. In hindsight, the Dubna results on 254No were probably correct and can be now considered a conclusive detection of element 102.
=== Medical === Desomorphine was previously used in Germany, Austria, and Switzerland for the treatment of severe pain. While medical usage of desomorphine was terminated in 1981, during the final years leading up to that it was being used to treat a single patient in Bern, Switzerland with a rare illness. While desomorphine was found to be faster acting and more effective than morphine for the rapid relief of severe pain, its shorter duration of action and the relatively more severe respiratory depression produced at equianalgesic doses, as well as a high incidence of other side effects such as hypotension and urinary retention, were felt to outweigh any potential advantages.
=== Ecuador's expulsion of Cuban ambassador === On 4 March 2026, Ecuador expelled Cuban Ambassador Basilio Gutierrez and his staff, declaring them persona non grata. No reason was provided for the expulsion.
Global Fossil Infrastructure Tracker API – the trade association of the US oil industry. (American Petroleum Institute) U.S. Energy Information Administration U.S. Department of Energy EIA – World supply and consumption Joint Organisations Data Initiative | Oil and Gas Data Transparency U.S. National Library of Medicine: Hazardous Substances Databank – Crude Oil "Petroleum" . The American Cyclopædia. 1879. "A Short History of Petroleum", Scientific American, August 10, 1878, p. 85
Sources: en.wikipedia.org
Retatrutide is an investigational synthetic peptide that activates three metabolic receptors: GLP-1, GIP, and glucagon. It is being studied for obesity and type 2 diabetes. It has not been approved for clinical use.
Earlier incretin therapies engage one or two receptors. Retatrutide adds glucagon receptor activity, which may raise energy expenditure. Whether this produces larger clinical benefits is still being tested.
It has completed phase 2 trials and moved into later-stage evaluation. No regulator has granted approval. Access outside research settings is not authorized.
Mass spectrometry provides the most direct confirmation of molecular mass. Reversed-phase chromatography adds a retention-time signature that supports identity when compared against a reference standard. No single method is sufficient on its own.